Lu Yang
Impact in
- Cancer Research top 1%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
- Cancer, Hypoxia, and Metabolism
- Molecular Biology top 2%
- Circular RNAs in diseases
- RNA modifications and cancer
- Epigenetics and DNA Methylation
Papers in
-
- Circular RNAs in diseases 12
- RNA modifications and cancer 6
- Epigenetics and DNA Methylation 4
- RNA Research and Splicing 3
-
- Cancer-related molecular mechanisms research 15
- MicroRNA in disease regulation 14
- Breast Cancer Treatment Studies 4
- Co-authors
- Hailin Tang (26 shared papers)Xiaoming Xie (26 shared papers)Yanan Kong (13 shared papers)Xinhua Xie (14 shared papers)Xiaojia Huang (11 shared papers)Jin Wang (3 shared papers)Weidong Wei (9 shared papers)Yingming Zhao (2 shared papers)
- Journals
- PLoS ONE (6 papers)Cancer Letters (5 papers)Frontiers in Oncology (3 papers)Cell Death and Disease (3 papers)Molecular Cancer (2 papers)
- Partner nations
- ChinaUnited StatesHong Kong
In The Last Decade
Lu Yang
85 papers receiving 3.9k citations
Lu Yang's Hit Papers
Peers
Comparison fields: 5 of 119
- Cancer Research 1.5k
- Molecular Biology 2.6k
- Oncology 705
- Geriatrics and Gerontology 41
- Immunology 232
Countries citing papers authored by Lu Yang
This map shows the geographic impact of Lu Yang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lu Yang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lu Yang more than expected).
Fields of papers citing papers by Lu Yang
This network shows the impact of papers produced by Lu Yang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lu Yang. The network helps show where Lu Yang may publish in the future.
Co-authors
The 25 scholars most cited alongside Lu Yang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 91 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Class I histone deacetylases (HDAC1–3) are histone lysine delactylases Hit paper breakdown → | 2022 | 495 |
| 2 | 2000 | 330 | |
| 3 | 2018 | 218 | |
| 4 | 2017 | 187 | |
| 5 | N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer Hit paper breakdown → | 2022 | 175 |
| 6 | 2019 | 167 | |
| 7 | 2015 | 137 | |
| 8 | 2022 | 126 | |
| 9 | 2021 | 113 | |
| 10 | 2013 | 109 | |
| 11 | 2022 | 104 | |
| 12 | 2014 | 102 | |
| 13 | 2013 | 101 | |
| 14 | 2014 | 90 | |
| 15 | 2020 | 90 | |
| 16 | 2014 | 85 | |
| 17 | 2015 | 83 | |
| 18 | 2019 | 73 | |
| 19 | 2015 | 69 | |
| 20 | 2018 | 58 |
About Lu Yang
Lu Yang is a scholar working on Molecular Biology, Cancer Research, Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine, having authored 91 papers that have together received 3.9k indexed citations. Recurring topics across this work include Cancer-related molecular mechanisms research (15 papers), MicroRNA in disease regulation (14 papers), Circular RNAs in diseases (12 papers), RNA modifications and cancer (6 papers), Breast Cancer Treatment Studies (4 papers), Cancer Cells and Metastasis (4 papers), Epigenetics and DNA Methylation (4 papers) and RNA Research and Splicing (3 papers). The work is most often cited by research in Cancer Research (1.5k citations), Molecular Biology (2.6k citations), Oncology (705 citations), Geriatrics and Gerontology (41 citations) and Immunology (232 citations). Lu Yang has collaborated with scholars based in China, United States and Hong Kong. Frequent co-authors include Hailin Tang, Xiaoming Xie, Yanan Kong, Xinhua Xie, Xiaojia Huang, Jin Wang, Weidong Wei, Yingming Zhao, John S. Mudgett and Jixiang Ding. Their work appears in journals such as PLoS ONE, Cancer Letters, Frontiers in Oncology, Cell Death and Disease and Molecular Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.